Lipid-Based Oral Formulation for Poorly Permeable Molecules
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Poorly permeable molecules, such as BCS Class III and Class IV compounds, face challenges with absorption through the intestinal membrane, requiring frequent intravenous or subcutaneous administration due to poor intestinal absorption and stability issues in the gastrointestinal tract.
Innovation Solution
Development of a lipid-based, water-free formulation with a lipophilic phase, lipophilic and hydrophilic surfactants, and optional stabilization agents, which forms a delayed release coated dosage form to enhance bioavailability by in-situ production of permeation enhancers, avoiding enzymatic degradation and chemical instability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If water is included in the formulation to solubilize the API, then the API can be dissolved, but the bioavailability of BCS Class III and IV compounds decreases due to aggregation
Solution Approach 1:
The patent changes the fundamental parameter of the formulation medium from aqueous to lipid-based. By using lipid excipients (triglycerides, phospholipids, cholesterol) instead of water as the continuous phase, the formulation creates a lipophilic environment that prevents aggregation of BCS Class III and IV compounds while maintaining their solubility and enhancing bioavailability.
Solution Approach 2:
The patent employs composite lipid-based excipients including triglycerides, phospholipids, and cholesterol in specific combinations. These composite lipid materials form a synergistic system that provides both solubilization capability for hydrophobic compounds and membrane permeation enhancement, resolving the contradiction between solubility and bioavailability.
2Loss of time
If the API is administered orally, then dosing frequency can be reduced, but absorption through the intestinal membrane is poor
Solution Approach 1:
The patent uses lipid-based excipients as intermediary substances that facilitate the transport of BCS Class III and IV compounds across the intestinal membrane. The lipid formulation acts as a carrier that enhances membrane permeation through mechanisms including dissolution- enhancement and direct incorporation into lipid bilayers, enabling effective oral absorption.
Solution Approach 2:
The patent utilizes phase transition properties of lipid excipients to enhance absorption. The lipid-based formulation undergoes phase changes in the gastrointestinal tract, transitioning from a liquid or semi-liquid state to facilitate compound release and membrane penetration, thereby improving oral bioavailability.
3Reliability
If the API is administered intravenously or subcutaneously, then absorption is ensured, but the need for frequent dosing increases
Solution Approach 1:
The patent designs the lipid-based formulation to be self-absorbing and self-sustaining in the gastrointestinal tract. The lipid excipients naturally interact with the intestinal membrane and facilitate compound absorption without requiring external intervention or frequent dosing, thereby achieving reliable absorption through oral administration with reduced dosing frequency.
4Ease of operation
If peptide or protein molecules are administered orally, then oral delivery is achieved, but chemical and physical instability occurs in the gastrointestinal tract
Solution Approach 1:
The patent creates a lipophilic protective environment that shields peptide and protein molecules from harsh gastrointestinal conditions. The lipid-based formulation acts as a protective matrix that reduces exposure to enzymes, acids, and other destabilizing factors, thereby maintaining chemical and physical stability of sensitive molecules during oral transit.
Solution Approach 2:
The lipid excipients serve as protective intermediaries that shield peptides and proteins from direct contact with destabilizing gastrointestinal factors. The lipid layer acts as a barrier that reduces enzymatic degradation and chemical modification, maintaining molecule integrity while enabling oral delivery.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulation achieves higher bioavailability and stability for poorly permeable molecules like peptides and proteins, allowing oral administration without frequent dosing, with enhanced absorption in the intestine using permeation enhancers.
Implementation Method 1
the formulation can enhance the permeation of the poorly permeable molecule through the intestinal membrane, thereby increasing the bioavailability of the molecule
Implementation Method 2
the formulation is inherently more physically stable because lipid excipients can be in solution as a single phase
Data Source
AI summary
The present disclosure is directed to a pharmaceutical formulation intended for oral delivery of synthetic or natural poorly permeable molecules or salts/solvates thereof having a therapeutic activity. The pharmaceutical formulation can include a synthetic or natural poorly permeable molecule or salt or solvate thereof in an amount 0.01-10 wt. % of the total weight of the formulation; a lipophilic phase comprising triglycerides of fatty acids in an amount of 50-80 wt. % of the total weight of the formulation; and at least one lipophilic surfactant comprising partial esters of polyol and fatty acids in an amount of about 10-50 wt. % of the total weight of the formulation.